GlassScriptPhysician profile
Timothy D Ashley
NPI 1043570617
$5,740.58
in general payments reported to CMS, 2019-2025
35 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $702 · 2021: $815 · 2022: $890 · 2023: $956 · 2024: $1,147 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,306.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $587.81 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.82 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Astrazeneca Pharmaceuticals LP | $488.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $338.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $325.54 | 2023-2024 | Rexulti |
| Abbott Laboratories | $261.42 | 2022-2023 | Freestyle Libre 2, Proclaim |
| Abbvie INC. | $249.53 | 2021-2024 | Ubrelvy, Qulipta |
| Amgen INC. | $203.65 | 2020-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $163.93 | 2020-2022 | |
| Glaxosmithkline, LLC. | $154.71 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $150.34 | 2019-2021 | |
| Horizon Therapeutics Plc | $145.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $114.08 | 2019 | |
| Exact Sciences Corporation | $109.49 | 2023-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $82.31 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $79.37 | 2022 | |
| Genentech USA, INC. | $63.89 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $49.70 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.62 | 2022-2025 | Xifaxan |
| Almatica Pharma LLC | $47.10 | 2024 | Loreev Xr |
| Sumitomo Pharma America, INC. | $39.11 | 2023 | Gemtesa |
| Corium, LLC | $32.37 | 2024 | Azstarys |
| Eisai INC. | $27.37 | 2020 | |
| Daiichi Sankyo INC. | $20.82 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.83 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $18.43 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $18.03 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $14.68 | 2025 | |
| Melinta Therapeutics, LLC | $14.28 | 2019 | |
| Lundbeck LLC | $13.47 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $13.08 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.84 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.66 | 2020 | |
| Allergan, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ashley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.